Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR
- Status
- COMPLETED
- Phase
- PHASE2
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
- Status
- UNKNOWN
- Phase
- PHASE1
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
- Status
- UNKNOWN
- Phase
- NA
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1
iCare for Cancer Patients
- Status
- TERMINATED
- Phase
- NA
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease
- Status
- TERMINATED
- Phase
- PHASE1
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia
- Status
- COMPLETED
- Phase
- PHASE2
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
- Status
- UNKNOWN
- Phase
- N/A
Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015
- Status
- COMPLETED
- Phase
- NA